FDA Approves First PSMA-Targeted Therapy for Metastatic Castration-Resistant Prostate Cancer by admin_63069 | Oct 14, 2024 | Related Topics Patients with PSMA-positive metastatic castration-resistant prostate cancer can now be treated with Pluvicto, which may provide hope to an unmet need in this patient population.
